{"doi":"10.1073/pnas.1518808112","title":"Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients","abstract":"<jats:title>Significance</jats:title>\n                  <jats:p>Emerging evidence indicates patients who benefit from antiangiogenic therapies have improved vessel function. To determine how bevacizumab modulates vessel morphology to improve vessel function we conducted a phase II trial of preoperative bevacizumab followed by bevacizumab combined with chemotherapy in HER2-negative breast cancer patients. Our results suggest that the clinical response to bevacizumab may occur through an increase in the extent of vascular normalization primarily in patients with a high baseline tumor microvessel density. If validated, these observations suggest approaches to improve antiangiogenic therapy and to identify patients likely to benefit.</jats:p>","journal":"Proceedings of the National Academy of Sciences","year":2015,"id":606949,"datarank":0.8329439377382427,"base_score":5.552959584921617,"endowment":5.552959584921617,"self_citation_contribution":0.8329439377382427,"citation_network_contribution":0.0,"self_endowment_contribution":0.8329439377382427,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":257,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":668335,"name":"Yves Boucher","orcid":"0000-0002-0334-3012","position":1,"is_corresponding":false},{"id":238100,"name":"Dan G. Duda","orcid":"0000-0001-7065-8797","position":2,"is_corresponding":false},{"id":914674,"name":"John D. Martin","orcid":"0000-0002-9828-8203","position":3,"is_corresponding":false},{"id":1558318,"name":"Giorgio Seano","orcid":null,"position":4,"is_corresponding":false},{"id":1183922,"name":"Marek Ancukiewicz","orcid":null,"position":5,"is_corresponding":false},{"id":333273,"name":"William T. Barry","orcid":null,"position":6,"is_corresponding":false},{"id":245471,"name":"Shom Goel","orcid":"0000-0001-8329-9084","position":7,"is_corresponding":false},{"id":1558319,"name":"Johanna Lahdenrata","orcid":null,"position":8,"is_corresponding":false},{"id":256299,"name":"Steven J. Isakoff","orcid":"0000-0002-6677-1014","position":9,"is_corresponding":false},{"id":1152845,"name":"Eren D. Yeh","orcid":"0000-0002-8939-1348","position":10,"is_corresponding":false},{"id":1558320,"name":"Saloni R. Jain","orcid":null,"position":11,"is_corresponding":false},{"id":396231,"name":"Mehra Golshan","orcid":null,"position":12,"is_corresponding":false},{"id":987021,"name":"Jane Brock","orcid":null,"position":13,"is_corresponding":false},{"id":236056,"name":"Matija Snuderl","orcid":"0000-0003-0752-0917","position":14,"is_corresponding":false},{"id":3752,"name":"Eric P. Winer","orcid":"0000-0002-8819-1723","position":15,"is_corresponding":false},{"id":231713,"name":"Ian E. Krop","orcid":"0000-0002-6380-5944","position":16,"is_corresponding":false},{"id":103964,"name":"Rakesh K. Jain","orcid":"0000-0001-7571-3548","position":17,"is_corresponding":false},{"id":56758,"name":"Sara M. Tolaney","orcid":"0000-0002-5940-8671","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients","abstract":"<jats:title>Significance</jats:title>\n                  <jats:p>Emerging evidence indicates patients who benefit from antiangiogenic therapies have improved vessel function. To determine how bevacizumab modulates vessel morphology to improve vessel function we conducted a phase II trial of preoperative bevacizumab followed by bevacizumab combined with chemotherapy in HER2-negative breast cancer patients. Our results suggest that the clinical response to bevacizumab may occur through an increase in the extent of vascular normalization primarily in patients with a high baseline tumor microvessel density. If validated, these observations suggest approaches to improve antiangiogenic therapy and to identify patients likely to benefit.</jats:p>","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"26578779","pmcid":"PMC4655544","openalex_id":null,"authors":[],"funders":[{"funder_name":"Genentech","grant_id":"Gen24357","title":null},{"funder_name":"HHS | NIH | National Cancer Institute","grant_id":"2P50 CA089393-08S2","title":null},{"funder_name":"U.S. Department of Defense","grant_id":"W81XWH-10-1-0016","title":null},{"funder_name":"Susan G. Komen for the Cure","grant_id":"PDF14301739","title":null},{"funder_name":"Associazione Italiana per la Ricerca sul Cancro","grant_id":"13604","title":null},{"funder_name":"HHS | NIH | National Cancer Institute","grant_id":"R01CA098706","title":null},{"funder_name":"NCI NIH HHS","grant_id":"P01 CA080124","title":null},{"funder_name":"NCI NIH HHS","grant_id":"P50 CA089393","title":null}],"total_grants":8,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"bronze","license":"cc-by","oa_locations":[{"url":"https://www.pnas.org/content/pnas/112/46/14325.full.pdf","host_type":"publisher"},{"url":"http://www.pnas.org/syndication/doi/10.1073/pnas.1518808112","host_type":"publisher"},{"url":"https://pnas.org/doi/pdf/10.1073/pnas.1518808112","host_type":"publisher"},{"url":"http://nrs.harvard.edu/urn-3:HUL.InstRepos:41482962","host_type":"repository"},{"url":"http://hdl.handle.net/1721.1/108678","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4655544","host_type":"repository"}],"fields_of_study":[],"mesh_terms":["Humans","Breast Neoplasms","Neovascularization, Pathologic","Antineoplastic Combined Chemotherapy Protocols","Neoadjuvant Therapy","Adult","Aged","Middle Aged","Female","Biomarkers, Tumor","Bevacizumab"],"keywords":["Antiangiogenic therapy","Cellular proliferation","Pam50 Gene Signature","Circulating And Tissue Biomarkers"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T05:27:38.594364Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}